Osteoporosis (Record no. 37951)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02542nam a22001817a 4500 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9780723433248 |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | MED RC931 |
| Item number | .O73 R675 |
| 100 ## - MAIN ENTRY--AUTHOR NAME | |
| Personal name | Ralston, Stuart H. |
| 245 ## - TITLE STATEMENT | |
| Title | Osteoporosis |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication | London |
| Name of publisher | Mosby Elsevier |
| Year of publication | 2002 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Number of Pages | vi, 104p. |
| Other physical details | ill. |
| 500 ## - GENERAL NOTE | |
| General note | <br/>Includes index |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | <br/>1. Introduction 2. Definition and Epidemiology 3. Pathophysiology 3.1 Bone structure 3.2 The cells of bone 3.3 Bone matrix 3.4 Bone remodelling 3.5 Regulation of bone mass and bone loss 3.5.1 Genetics 3.5.2 Sex hormones 3.5.3 Diet 3.5.4 Exercise 3.5.5 Smoking 3.5.6 Alcohol 3.5.7 Other risk factors 3.6 Diseases and drugs 3.6.1 Chronic Inflammatory disease 3.6.2 Gastrointestinal Disease 3.6.3 Thyrotoxicosis 3.6.4 Primary Hyperparathyroidism 3.6.5 Hypogonadism 3.6.6 Corticosteroids 3.6.7 Other drugs 4. Investigation and Diagnosis 4.1 Clinical Assessment 4.2 Bone densitometry 4.3 Quantitative Ultrasound 4.4 Plain Radiographs 4.5 Other Imaging techniques 4.6 Bone turnover markers 4.7 Genetic markers 4.8 Routine Biochemistry and haematology 4.9 Bone biopsy 5. Prevention of Osteoporosis 5.1 When should preventative treatment be used? 5.1.1 Diet 5.1.2 Exercise 5.1.3 Smoking alcohol and other factors 5.1.4 Calcium and vitamin D 5.1.5 HRT 5.1.6 Raloxifene 5.1.7 Tibolone 5.1.8 Bisphosphonates (Etidronate, Alendronate, Risedronate) 5.1.9 Agents in development (Zoledronate, Ibandronate) 6. Treatment of established osteoporosis 6.1 When should treatment be given? 6.1.1 Calcium and vitamin D 6.1.2 Active vitamin D metabolites 6.1.3 Calcitonin 6.1.4 Fluoride 6.1.5 Raloxifene 6.1.6 Cyclic etidronate, 6.1.7 Alendronate, 6.1.8 Risedronate 6.1.9 Agents in development (PTH, Zoledronate, Ibandronate) 7. Corticosteroid induced osteoporosis 7.1 Pathogenesis 7.2 Investigation 7.3 Prevention and Treatment 8. Osteoporosis in men 8.1 Pathogenesis 8.2 Investigation 8.3 Treatment 9. Osteogenesis imperfecta 9.1 Pathogenesis 9.2 Investigation 9.3 Treatment 10. Rare causes of osteoporosis 11. Frequently Asked Questions 12. References Appendix 1 - Drug treatments and doses Appendix 2 - Useful addresses and websites Index<br/> |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | This reference is designed by clinical specialists to assist with treatment decisions. Each title in the 'Rapid Reference' series provides standard core content combined with the additional information, such as FAQs and patient organizations, needed by the GP to provide effective patient care<br/> |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical Term | Osteoporosis |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kleerekoper, Michael. (author) |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Books |
| Withdrawn status | Lost status | Not for loan | Home library | Current library | Shelving location | Date entered | Source of acquisition | Cost, normal purchase price | Full call number | Bar code | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Directorate of Library Services | Directorate of Library Services | General Collection | 08/23/2024 | Gifted of Sabre Foundation USA | 51490.00 | MED RC931.O73 R675 | 000000014636 | Books |